CTL
Showing 1 - 25 of 549
Lymphoma, B-Cell Trial in Philadelphia (CD19 redirected autologous T cells (CTL019 or CTL119 cells))
Not yet recruiting
- Lymphoma, B-Cell
- CD19 redirected autologous T cells (CTL019 or CTL119 cells)
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Mar 18, 2022
Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy Trial in London (Autologous EBV-CTL
Active, not recruiting
- Post-transplant Lymphoproliferative Disease
- Transplant-Related Hematologic Malignancy
- Autologous EBV-CTL transduced with vector SFG-CNA12
- +2 more
-
London, United Kingdom
- +1 more
Jan 19, 2022
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- Tisagenlecleucel
- Lymphodepleting chemotherapy
-
San Francisco, California
- +25 more
Jan 27, 2023
Health, Subjective Trial in Seoul (CTL0801 (Azilsartan), CTL0802 (Rosuvastatin), CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin))
Completed
- Health, Subjective
- CTL0801 (Azilsartan)
- +2 more
-
Seoul, Korea, Republic ofH Plus Yangji Hospital
Dec 21, 2021
Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection Trial in Houston (Virus-specific Cytotoxic T-lymphocytes)
Recruiting
- Adenovirus Infection
- +6 more
- Virus-specific Cytotoxic T-lymphocytes
-
Houston, TexasM D Anderson Cancer Center
Jan 6, 2023
Health, Subjective Trial in Seoul (Drug: Treatment A, Drug: Treatment B, Drug: Treatment C)
Completed
- Health, Subjective
- Drug: Treatment A
- +2 more
-
Seoul, Korea, Republic ofH Plus Yangji Hospital
Dec 21, 2021
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor Trial in Columbus (Allogeneic
Recruiting
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +3 more
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
-
Columbus, Ohio
- +1 more
Apr 20, 2022
Solid Tumor, Adult Trial in Germany, Spain, Switzerland (CTL-002)
Recruiting
- Solid Tumor, Adult
- CTL-002
-
Essen, Germany
- +5 more
Mar 2, 2022
Lower-Limb Amputation Trial in Aurora (Exercise self-management, Attention control)
Recruiting
- Lower-Limb Amputation
- Exercise self-management
- Attention control
-
Aurora, ColoradoRocky Mountain Regional VA Medical Center, Aurora, CO
Dec 23, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Worldwide (CTL019)
Active, not recruiting
- B-cell Acute Lymphoblastic Leukemia
- CTL019
-
Los Angeles, California
- +24 more
Jun 23, 2022
Solid Tumors Trial in Washington (Tumor associated antigen lymphocytes (TAA-CTL))
Active, not recruiting
- Solid Tumors
- Tumor associated antigen lymphocytes (TAA-CTL)
-
Washington, District of ColumbiaChildren's National Medical Center
Jun 1, 2022
Inflammation Trial in Kelowna (Moderate intensity continuous exercise, High intensity continuous exercise, High intensity
Recruiting
- Inflammation
- Moderate intensity continuous exercise
- +3 more
-
Kelowna, British Columbia, CanadaUBC Okanagan
Oct 6, 2022
BK Polyomavirus Trial in Philadelphia (BK-virus specific CTLs)
Recruiting
- BK Polyomavirus
- BK-virus specific CTLs
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Mar 15, 2022
Serologically Active Adult Systemic Lupus Erythematosus Trial in Nantes, Paris (Autologous EBV specific CTL infusion)
Terminated
- Serologically Active Adult Systemic Lupus Erythematosus
- Autologous EBV specific CTL infusion
-
Nantes, France
- +2 more
Mar 24, 2022
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,
Recruiting
- Hodgkin Disease
- +5 more
- MABEL CTLs
- +2 more
-
Houston, Texas
- +1 more
Jan 13, 2023
B-Cell Acute Lymphoblastic Leukemia Trial in Shenzhen (Antigen-specific T cells CART/CTL and DCvac)
Recruiting
- B-Cell Acute Lymphoblastic Leukemia
- Antigen-specific T cells CART/CTL and DCvac
-
Shenzhen, Guangdong, ChinaShenzhen Geno-Immune Medical Institute
Mar 7, 2022
Malignant Tumor Trial in Shenzhen (DC-CTL)
Recruiting
- Malignant Tumor
- DC-CTL
-
Shenzhen, Guangdong, ChinaShenzhen University General Hospital
Dec 16, 2020
Melanoma Trial in Fairway (tvs-CTL Vaccine)
Completed
- Melanoma
- tvs-CTL Vaccine
-
Fairway, KansasKU Cancer Center
Jan 20, 2022
EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) Trial in Switzerland (Donor-derived ex-vivo expanded EBV Tscm
Not yet recruiting
- EBV Lymphoma
- Post-transplant Lymphoproliferative Disease (PTLD)
- Donor-derived ex-vivo expanded EBV Tscm CTL
-
Basel, Switzerland
- +7 more
Jan 25, 2023
T-Cell Acute Lymphoblastic Leukemia Trial in Shenzhen (Antigen-specific T cells CAR-T/CTL and DCvac)
Recruiting
- T-Cell Acute Lymphoblastic Leukemia
- Antigen-specific T cells CAR-T/CTL and DCvac
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Mar 14, 2022
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program Trial in Worldwide
Recruiting
- Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
- Previously treated CAR-T patients
-
Phoenix, Arizona
- +71 more
Nov 14, 2022
B-cell Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel)
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- Tisagenlecleucel
- (no location specified)
Feb 3, 2022